Belongtail Ltd.

Belongtail Ltd. provides innovative digital health solutions that enhance patient engagement through advanced technology and AI-driven platforms, focusing on chronic disease management and personalized support for patients. Founded in 2014 in New York, US, Belongtail Ltd. specializes in digital health solutions that empower patients with chronic diseases.

The company was led by CEO Eliran Malki, who has previously founded other ventures. In July 2019, Belongtail Ltd. raised USD 14. 000 mn in Series B funding, with IQVIA, Inc.

as a lead investor, bringing the total amount raised to USD 14. 000 mn. Belongtail Ltd. specializes in digital health solutions that enhance patient engagement through innovative technology and data-driven platforms.

The company's core offerings include the BelongAI health-grade patient engagement and support platforms, which feature proprietary AI health mentors such as Dave AI Cancer Mentor, Sophie AI MS Mentor, and Tara AI Clinical Trials Matching Assistant. These applications aim to empower patients with chronic diseases, particularly those living with cancer and multiple sclerosis, providing them with personalized guidance and proactive support from a community of peers. The platforms are designed to streamline patient care processes and improve the overall quality of life by offering access to vast educational libraries, community resources, and secure data management. Belongtail Ltd.

's products are marketed to healthcare providers, pharmaceutical companies, and payers across various regions, including North America, Europe, and Asia, thus enabling a global reach and impactful patient engagement. Belongtail Ltd. generates revenue primarily through subscriptions for its AI-driven health mentor applications and partnerships with healthcare organizations. Clients, including hospitals, clinics, and pharmaceutical companies, engage with the company to implement these platforms within their service offerings, facilitating seamless patient management and support.

Transactions typically occur on a B2B basis, where healthcare providers subscribe to access comprehensive patient engagement tools, thereby enhancing their service capabilities. The company’s flagship products, such as the Dave AI Cancer Mentor and the Sophie AI MS Mentor, feature tiered pricing plans that may vary based on the scale of implementation and included services. This structured approach allows Belongtail Ltd. to cater to a diverse client base while ensuring steady revenue streams through annual or monthly subscriptions that support ongoing development and updates to their digital health solutions.

Following the Series B funding round completed in July 2019, Belongtail Ltd. plans to invest in the development of new AI-driven health solutions to enhance patient engagement further. The company is also targeting expansion into new markets across Asia and Europe by 2022, aiming to increase its global presence. The funding will be utilized to enhance product features, improve customer support, and expand marketing efforts in these regions.